Trial ID 11282 | Maryland Oncology Hematology Trial ID 11282 – Maryland Oncology Hematology

Trial ID 11282

Trial Information - Phase II

A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Protocol ID: SGN35-015

Sponsor: Seatlte Genetics. Inc.

Status: STAR TRIAL

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Lymphoma

Status

STAR TRIAL

Sponsor

Seatlte Genetics. Inc.

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology